The Nasdaq Stock Market will list its first cannabis shares on Tuesday, marking a key milestone for an industry that has been rejected by the Trump administration.
Tag Archives: shares
For all that’s worked in favor of marijuana stocks in recent years, there are plenty of risks. Some of these risks, such as profitability eluding most pot stocks, are readily apparent.
Two of the top 10 most-traded shares in Sweden in January 2018 were Canada marijuana stocks, adding further proof that the marijuana market is growing more global with each passing day.
Canada’s No. 2 marijuana producer Aurora Cannabis Inc has agreed to buy smaller rival CanniMed Therapeutics Inc for C$1.1 billion ($852 million) as companies jostle to benefit from the country’s legalization of recreational marijuana use later this year.
Investors are betting Canada’s smaller financial firms could see a jump in revenues after they helped fund marijuana companies ahead of the country’s planned legalization of the drug this year.
Australia said on Thursday it planned to become the fourth country in the world to legalise medicinal marijuana exports in a bid to score a piece of the estimated $55 billion global market.
Medical marijuana maker CanniMed Therapeutics Inc (CMED.TO) should withdraw a shareholder rights plan adopted to fend off a hostile bid from larger rival Aurora Cannibis Inc ABC.TO, two Canadian regulators have ruled.
VICTORIA, British Columbia, Dec. 21, 2017 /Weed Wire/ — Emerald Health Therapeutics Inc. (“Emerald” or the “Company”) (TSXV: EMH; OTCQX: EMHTF) has elected to exercise its right to accelerate the exercise of $2.00 common share purchase warrants (“Warrants”) issued by the Company on February 10, 2017.
Investors have been eager to enter the Canadian marijuana space as the country moves towards launching its recreational cannabis market next July.
Medical marijuana company Aurora Cannabis Inc said on Monday its acquisition-target CanniMed Therapeutics Inc’s plan to buy smaller rival Newstrike Resources Ltd was a “terrible deal” for CanniMed shareholders.
Canada’s Aurora Cannabis Inc (ACB.TO) said on Monday it increased its stake in Australia-based Cann Group Ltd (CAN.AX) to 22.9 percent from 19.9 percent, its latest move to expand in the cannabis industry.
The first U.S. exchange-traded fund, ETF, to focus on marijuana stocks is launching Dec. 26 — days before California legalizes recreational cannabis use on January 1.
VICTORIA, British Columbia, Nov. 29, 2017 /Weed Wire/ — Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF) (“Emerald” or the “Company”) announces that it acquired today 1,666,6667 units (the “Units”) of Vanc Pharmaceuticals Inc. (“Vanc”) of Suite 810 – 789 West Pender Street, Vancouver, British Columbia, V6C 1H2 at a price of $0.15 per Unit pursuant to a private placement offering (the “Transaction”).
Not surprisingly, Canadian pot stocks have been the top performers of late, with Canopy Growth Corp. (NASDAQOTH:TWMJF), the now-largest marijuana stock in the world by market cap, leading the charge.
Vancouver-based Aurora Cannabis Inc. said Tuesday that it has made an all-share offer for CanniMed Therapeutics Inc., a fellow Canadian medical marijuana company.
Shares of Canopy Growth Corp. (TSX:WEED) have climbed a stunning 53.8% month over month as of close on November 1. With all of this in mind, has Canopy established itself as the premier cannabis stock for Canadians?
The Auscann Group Holdings Ltd (ASX: AC8) share price had a day to remember on Tuesday. At one stage the medicinal cannabis company’s shares were up as much as 27% before finishing the day 23.5% higher at 52.5 cents.
Shares of Insys Therapeutics, a small-cap biotech with a focus on pain management, plunged as much as 30% on Wednesday after receiving a double whammy.
PALO ALTO, Calif., Oct. 18, 2017 /Weed Wire/ — Plus, the cannabis infused products manufacturer, is pleased to announce the closing of its Series A financing (the “Financing”). The Financing was comprised of $2 Million USD of Series A Preferred Stock (the “Shares”), and was led by The Green Opportunity Funds (TGOF)
Shares of Canadian marijuana company Aphria Inc sank on Tuesday, after the operator of the Toronto Stock Exchange said cannabis companies with U.S. interests would come under heightened scrutiny and could be delisted.
Legal pot sales rose a stunning 34% in 2016 to $6.7 billion across North America, according to Arcview Market Research. But with growth this rapid, there’s bound to be more than a few marijuana stock investments that will be left behind.
Canada’s biggest medical cannabis producers are seeing their stock prices rise after the federal government announced a plan to levy a one dollar per gram tax on recreational marijuana sales.
Marijuana companies should be careful in overselling how much growth will be achieved or what the prospects will look like for the industry. There is a recent example that cannabis investors would be wise to review, and that’s what happened with Freshii Inc..
Zynerba Pharmaceuticals Inc said on Thursday its cannabis-based gel met the main goal in a mid-stage study of patients with Fragile X syndrome, a genetic disorder that causes learning disabilities in adolescents and children.
Arizona’s attorney general is suing Insys Therapeutics over its marketing of the fentanyl opioid spray, Subsys, and that news caused the company’s shares to tumble 18.5% in August, according to S&P Global Market Intelligence.
Further to the ASX announcement dated 29 August 2017 title ‘Priority Share Offer for CannPal Animal Therapeutics Ltd IPO Shares’, the Board of Zelda Therapeutics Ltd wishes to clarify the Priority Offer Record Date.
Canopy Growth Corp. (TSX:WEED) was the first cannabis stock to the market and quickly captured the attention of traders and risk-taking growth investors alike. As a result, shares of Canopy skyrocketed 300% in a span of just a few months last year.
There has been a lot of news in the marijuana industry this year. The medical marijuana industry exploded, and many new companies came to market in a frenzy, which reminded investors of the exciting technology bubble.
Clinical-stage cannabinoid-based drug developer Zynerba Pharmaceuticals (NASDAQ:ZYNE) had been one of the strongest-performing pot stocks over the trailing year prior to the start of this past week.
When GW Pharmaceuticals announced its fiscal third-quarter results on Monday, the company provided plenty of information about its performance during the quarter. However, it wasn’t any of the numbers in the update that caused this decline. Instead, one word caused investors’ disappointment.
Zynerba Pharmaceuticals Inc said on Monday its synthetic cannabis-based gel to treat epilepsy failed a mid-stage study, sending the U.S. drug developer’s shares plunging 50 percent.
For many weed stocks, the summer of 2017 hasn’t been what you’d call a scorcher. However, three marijuana stocks have sizzled this summer.
In mid-June home lawn and fertilizer care specialist The Scotts Miracle-Gro Company (NYSE:SMG) lowered its full-year fiscal 2017 outlook, citing a more than 10% drop in mass retail sales compared to the year-to-date checkpoint from the previous year. That was caused by challenging weather this spring in core markets across the United States.
The Creso Pharma Ltd (ASX: CPH) share price has been amongst the biggest movers on the market this morning. This morning the company revealed that it plans to expand into the Canadian market.
Well, we have news for Canadian marijuana stock investors: There’s a new threat on the horizon, at least for our neighbors to the north.
The Auscann Group Holdings Ltd share price has continued its strong run and is up a further 6% to 46 cents today. Why has it jumped? Let’s look to find out.
MedReleaf is one of less than four dozen licensed producers and retailers of medical cannabis products in Canada. The company was founded just four years ago, and it focuses on supplying dried cannabis, cannabis oils, and cannabis oil capsules to qualified medical patients in Canada.
Warren Buffett is well known as the most successful investor of all time. Buffett spent his formative years under the tutelage of Benjamin Graham, who is known today as the “father of value investing.” Let’s see whether or not Aphria Inc. can pass Buffett’s mentor’s criteriea test.
Shares of Cara Therapeutics Inc., a clinical-stage biotech company with a focus on treating pain and pruritus, rocketed higher by as much as 11% during Wednesday’s trading session after providing an update to its phase 3 trial involving kappa opioid receptor agonist CR845.
Though there are a number of direct players in the industry, some of the most surprising growth can be seen in emerging industry players. One such name is Scotts Miracle-Gro.
The industry and the Canopy Growth Corp. were going to be the next big thing for investors, but things have cooled down gradually over the past few months.
Thanks to a 2% gain to 49 cents today, the Cann Group Ltd (ASX: CAN) share price has now risen over 63% since hitting the ASX boards.
Multi-state cannabis company iAnthus Capital Management has now planted its flag in New York with Monday’s announced acquisition of Valley Agriceuticals.
The threat of increasing competition for GW Pharmaceuticals’ promising epilepsy drug took a toll on investors’ confidence last month.
Oh, how the mighty have fallen. Shares of Canopy Growth Corp. have dropped by over $6 a share, or 47.5%, since the middle of February.
Aurora Cannabis Inc. has been a favourite marijuana stock for some time. Should you be watching closely for an opportunity to buy the dip?
While investors holding for the past year have still made a positive return, there may not be much room left for marijuana companies’ shares to run higher.
There is an opportunity for excess profits in the Canadian marijuana industry as the market is now in a position to expand at a very high rate, as Canadians have received confirmation that the potential legalization will become a reality.
Insiders with two of Canada’s largest marijuana companies are cashing in on the industry’s reefer madness before the country introduces its plans for legalized recreational pot.
While shares have backed off the 52 week highs, Aurora Cannabis is making another run towards the highs as investor enthusiasm increases over recreational marijuana legalization in Canada. Here’s the insider scoop and why we like Aurora Cannabis Inc.